“…Using the latter approach we have sought to characterize the P-adrenoceptors that mediate inhibition of gastric secretion by studying the non-selective ,B-adrenoceptor agonist isoprenaline (Ekue, Shanks & Zaidi, 1971), the #2-selective agonist salbutamol (Cullum, Farmer, Jack & Levy, 1969) and their interactions with the /3l-and #2-adrenoceptor antagonist propranolol (Shanks, 1966), the fil-selective antagonist practolol (Dunlop & Shanks, 1968) and the f2-selective antagonist H35/25 (Levy, 1967). (+)-Propranolol, the inactive isomer of propranolol, was used as a control for effects unrelated to ,B-adrenoceptor blockade (Howe & Shanks, 1966).…”